Background Heterogeneity of cerebral atrophic rate commonly exists in mild cognitive
impairment (MCI), which may be associated with microglia-involved neuropathology and …

Background The hypothetical model of dynamic biomarkers for Alzheimer's disease (AD)
describes high amyloid deposition and hypometabolism at the mild cognitive impairment …

Background and Purpose: It is well known that there is a wide range of different pathological
stages related to Alzheimer's disease (AD) among patients with amnestic mild cognitive …

This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI)
within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the …

Introduction Subtle cognitive impairment (SCI) may appear before pathological changes
surpass thresholds for abnormality. We aimed to investigate whether SCI could predict …

In recent years, amnestic mild cognitive impairment (aMCI) has attracted significant attention
as an indicator of high risk for Alzheimer's disease. An understanding of the pathology of …

The objective of this study was to evaluate the A/T/N biomarker scheme in relation with brain
atrophy patterns in individuals with mild cognitive impairment (MCI). Of the 154 participants …

Only a third of individuals with mild cognitive impairment (MCI) progress to dementia of the
Alzheimer's type (DAT). Identifying biomarkers that distinguish individuals with MCI who will …

Background Previous work examining normal controls from the Alzheimer's Disease
Neuroimaging Initiative (ADNI) identified substantial biological heterogeneity. We …

Background Mild behavioral impairment (MBI) is a neurobehavioral syndrome characterized
by later life emergence of sustained neuropsychiatric symptoms, as an at-risk state for …